FDA Antiviral Drugs Advisory Committee
Executive Summary
Panel's inaugural meeting will focus on expanded indications for Burroughs Wellcome's AZT (Zidovudine) on Jan. 29. On Jan. 30, ongoing trials with Bristol-Myers' DDI may be discussed as part of an FDA update on the status of expanded availability of AIDS drugs. Committee will meet at Bethesda Hyatt Regency Hotel beginning each morning at 8:30 a.m.